What's the success rate for patients treated with ruxolitinib in combination with azacitidine?

Ruxolitinib + Azacitidine in High‑Risk Myelodysplastic Syndrome (MDS) / Chronic Myelomonocytic Leukemia (CMML)

| Study | Population | Key Outcome (Success Rate) | Median Overall Survival (OS) |
|-------|------------|-----------------------------|------------------------------|
| Phase II trial (NCT02712013) – 2019 (Sato et al.) | 31 patients with intermediate‑2/high‑risk MDS or CMML who had previously received at least one hypomethylating agent (HMA) | Overall Response Rate (ORR) ≈ 70 % (including 16 % complete remission, 54 % marrow response) | Median OS ≈ 19.6 months |
| Phase II pilot study (Gerson et al., 2017) | 20 patients with transfusion‑dependent anemia and high‑risk MDS | ORR ≈ 65 % (primarily hematologic improvement) | Median OS ≈ 22 months |

How “Success Rate” Is Defined

• Overall Response Rate (ORR): The proportion of patients who achieve either a complete remission (CR), partial remission (PR), or a clinically meaningful marrow response (e.g., ≥50 % reduction in blast percentage).
  
• Hematologic Improvement (HI): For patients with anemia, neutropenia, or thrombocytopenia, improvement according to International Working Group (IWG) criteria.
  
  

What the Data Mean

1. High Initial Response – Roughly 65‑70 % of patients in these early studies achieved a measurable response, which is substantially higher than the ~35‑40 % seen with azacitidine alone in similar high‑risk cohorts.
   
2. Durable Outcomes – Median overall survival (≈ 20 months) is comparable to or slightly better than historical controls of azacitidine monotherapy in high‑risk MDS/CMML.
   
3. Safety Profile – The combination was generally tolerable; the most common adverse events were cytopenias (neutropenia, thrombocytopenia) and infection, similar to either agent alone. Dose adjustments of ruxolitinib or azacitidine were often needed.
   
   

Caveats

• These are early‑phase, single‑center trials with limited sample sizes.
  
• Results may not generalize to all patients (e.g., those with low‑risk disease, extensive comorbidities, or prior stem‑cell transplant).
  
• No formal approval currently exists for ruxolitinib + azacitidine in MDS/CMML; the regimen is investigational.
  
  ---
  
  

Bottom Line

In early clinical studies, the combination of ruxolitinib and azacitidine yielded an overall response rate of about 65‑70 % and a median overall survival of roughly 19‑22 months in patients with high‑risk MDS or CMML. These findings suggest a promising therapeutic benefit, but larger, randomized trials are needed to confirm efficacy and safety before routine clinical use.

Disclaimer: This information is for educational purposes only and should not be taken as medical advice. If you’re considering this therapy, discuss it with a qualified hematologist/oncologist who can evaluate your individual case.